Publication | Closed Access

Pegylated liposomal formulation of doxorubicin overcomes drug resistance in a genetically engineered mouse model of breast cancer

Health SciencesPolymer-drug ConjugateMedicineBreast CancerTumor TargetingAnti-cancer AgentDrug DevelopmentLiposomal FormulationPharmacologyRadiation OncologyMouse ModelDrug DiscoveryDrug Resistance